Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid

Dai, Ding; C. Zeldin, Darryl; Blaisdell, Joyce; Chanas, Brian; J. Coulter, Sherry; I. Ghanayem, Burhan; A. Goldstein, Joyce

doi:10.1097/00008571-200110000-00006

Public

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid

Published in Pharmacogenetics • Oct 1, 2001

Authors:

Ding Dai

Darryl C. Zeldin

Joyce Blaisdell

Abstract

Cytochrome P450 (CYP) 2C8 is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (Taxol). It is also the predominant P450 responsible for the metabolism of arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs) in human liver and kidney. In this s...

Subject

CYP2C8

Arachidonic acid

CYP2C9

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!